Business

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026.

articleProtalix Biotherapeutics, Inc. (de)May 6, 20263/company/protalix-biotherapeutics-inc-de/news/protalix-biotherapeutics-to-announce-first-quarter-2026-financial-results-and-business-update-on-may-13-2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

About this update from Protalix Biotherapeutics, Inc. (de)

[{"type":"text","content":"Company to host conference call and webcast at 8:00 a.m. EDT","length":60,"tagName":"p","attribs":{}},{"type":"text","content":"CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026.","length":431,"tagName":"p"},{"type":"image","alt":"Protalix Biotherapeutics Logo","displaySize":"","headline":null,"caption":"Protalix Biotherapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oqa0M0mcI48Gcrf3B95o9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMw--/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RPQUtZ31VT6hmLALPDIzRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE5NA--/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121}}},{"type":"text","content":"Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.","length":142,"tagName":"p"},{"type":"text","content":"Conference Call Details:Date: Wednesday, May 13, 2026Time: 8:00 a.m. Eastern Daylight Time (EDT)Toll Free: 1-877-423-9813International: 1-201-689-8573Israeli Toll Free: 1-809-406-247Conference ID: 13760475Call me™: https://tinyurl.com/yjww2vxn","length":251,"tagName":"p"},{"type":"text","content":"The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.","length":147,"tagName":"p"},{"type":"text","content":"Webcast Details: The conference will be webcast live from the Protalix website and will be available via the following links:","length":131,"tagName":"p"},{"type":"text","content":"Company Link: https://ir.protalix.com/news-events/eventsWebcast Link: https://tinyurl.com/ykmy9jmrConference ID: 13760475","...

More updates from Protalix Biotherapeutics, Inc. (de)

Protalix BioTherapeuticsbiopharmaceutical companyrare diseasesfinancial resultscommercialization